IL101633A - History of dipeptide transformed by phosphono / biarril, their preparation and pharmaceutical preparations containing them - Google Patents

History of dipeptide transformed by phosphono / biarril, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL101633A
IL101633A IL10163392A IL10163392A IL101633A IL 101633 A IL101633 A IL 101633A IL 10163392 A IL10163392 A IL 10163392A IL 10163392 A IL10163392 A IL 10163392A IL 101633 A IL101633 A IL 101633A
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
propionyl
acceptable salt
biphenylyl
phosphonomethylamino
Prior art date
Application number
IL10163392A
Other languages
English (en)
Hebrew (he)
Other versions
IL101633A0 (en
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of IL101633A0 publication Critical patent/IL101633A0/xx
Publication of IL101633A publication Critical patent/IL101633A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10163392A 1991-05-01 1992-04-17 History of dipeptide transformed by phosphono / biarril, their preparation and pharmaceutical preparations containing them IL101633A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/694,533 US5155100A (en) 1991-05-01 1991-05-01 Phosphono/biaryl substituted dipeptide derivatives

Publications (2)

Publication Number Publication Date
IL101633A0 IL101633A0 (en) 1992-12-30
IL101633A true IL101633A (en) 1996-03-31

Family

ID=24789228

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10163392A IL101633A (en) 1991-05-01 1992-04-17 History of dipeptide transformed by phosphono / biarril, their preparation and pharmaceutical preparations containing them

Country Status (15)

Country Link
US (1) US5155100A (fi)
EP (1) EP0511940A3 (fi)
JP (1) JPH05170792A (fi)
KR (1) KR920021578A (fi)
AU (1) AU655252B2 (fi)
CA (1) CA2067592A1 (fi)
FI (1) FI921884A (fi)
HU (1) HUT61032A (fi)
IE (1) IE921401A1 (fi)
IL (1) IL101633A (fi)
MX (1) MX9201953A (fi)
NO (1) NO921719L (fi)
NZ (1) NZ242546A (fi)
TW (1) TW208704B (fi)
ZA (1) ZA923164B (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5294632A (en) * 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
JP3130938B2 (ja) * 1991-10-22 2001-01-31 オーストリア・タバクヴェルケ・アクチエンゲゼルシャフトヴォマー・オーシュターライヒッシェ・タバコレジー シガレットフィルター
US5273990A (en) * 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
JPH05148277A (ja) * 1991-11-05 1993-06-15 Banyu Pharmaceut Co Ltd アミノホスホン酸誘導体
IT1266570B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
WO1995013817A1 (en) * 1993-11-18 1995-05-26 Smithkline Beecham Corporation Endothelin converting enzyme inhibitors
IT1274673B (it) * 1994-04-14 1997-07-24 Zambon Spa Derivati dell'acido fosfonico utili nel trattamento delle malattie car.iovascolari
IT1270260B (it) * 1994-06-21 1997-04-29 Zambon Spa Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
US5583123A (en) * 1994-12-22 1996-12-10 Ciba-Geigy Corporation Certain tetrazole derivatives
US5635103A (en) 1995-01-20 1997-06-03 The Procter & Gamble Company Bleaching compositions and additives comprising bleach activators having alpha-modified lactam leaving-groups
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
WO1997011717A1 (en) * 1995-09-27 1997-04-03 Novartis Ag Treatment of chronic progressive renal failure
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
MXPA01009654A (es) * 1999-03-29 2002-05-14 Squibb Bristol Myers Co Uso de inhibidores de la vasopeptidasa para tratar la angina de pecho.
WO2007083774A1 (ja) * 2006-01-17 2007-07-26 Sumitomo Chemical Company, Limited ビフェニルメチルヒダントイン化合物、その製造方法、及びそれを用いるビフェニルアラニン化合物の製造方法
JP2007191446A (ja) * 2006-01-20 2007-08-02 Sumitomo Chemical Co Ltd ビフェニルメチルヒダントイン化合物、その製造方法、及びそれを用いるビフェニルアラニン化合物の製造方法
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
JP2008260755A (ja) * 2007-03-20 2008-10-30 Sumitomo Chemical Co Ltd L−ビフェニルアラニン化合物の塩の回収方法、およびそれを用いたビフェニルアラニンエステル化合物の回収方法
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
JP2011506459A (ja) 2007-12-11 2011-03-03 セラヴァンス, インコーポレーテッド 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
WO2009134741A1 (en) 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
EP2456762B1 (en) 2009-07-22 2013-10-16 Theravance, Inc. Dual-acting oxazole antihypertensive agents
US8481549B2 (en) 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
MX354476B (es) 2010-12-15 2018-03-07 Theravance Inc Inhibidores de neprilisina.
AU2011343899B2 (en) 2010-12-15 2016-06-30 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
WO2012112742A1 (en) 2011-02-17 2012-08-23 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
ES2564275T3 (es) 2011-02-17 2016-03-21 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CA2835216A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
CN103582630B (zh) 2011-05-31 2016-08-17 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
US8686184B2 (en) 2011-05-31 2014-04-01 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CA2871292A1 (en) 2012-05-31 2013-12-05 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
US8871792B2 (en) 2012-06-08 2014-10-28 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
AU2013271537B2 (en) 2012-06-08 2017-05-11 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
JP6092390B2 (ja) 2012-08-08 2017-03-08 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
DK2956464T3 (en) 2013-02-14 2018-07-16 Novartis Ag Substituted bisphenyl-butane phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
EP2964616B1 (en) 2013-03-05 2017-05-03 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
EP3024492A2 (en) 2013-07-25 2016-06-01 Novartis AG Bioconjugates of synthetic apelin polypeptides
PE20160878A1 (es) 2013-07-25 2016-09-08 Novartis Ag Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
AU2015211041B2 (en) 2014-01-30 2018-11-08 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
CA2934936A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
CU20170093A7 (es) 2015-01-23 2017-09-06 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
US9433598B2 (en) 2015-02-11 2016-09-06 Theravance Biopharma R&D Ip, Llc (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid
JP6714009B2 (ja) 2015-02-19 2020-06-24 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー (2r,4r)−5−(5’−クロロ−2’−フルオロビフェニル−4−イル)−2−ヒドロキシ−4−[(5−メチルオキサゾール−2−カルボニル)アミノ]ペンタン酸
TWI731943B (zh) 2016-03-08 2021-07-01 美商施萬生物製藥研發Ip有限責任公司 結晶型(2s,4r)-5-(5’-氯-2’-氟-[1,1’-聯苯]-4-基)-2-(乙氧基甲基)-4-(3-羥基異㗁唑-5-甲醯胺基)-2-甲基戊酸及其用途
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP2022509184A (ja) 2018-11-27 2022-01-20 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
EP3887363A1 (en) 2018-11-27 2021-10-06 Novartis AG Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE141930C (fi) * 1900-01-01
US4053505A (en) * 1976-01-05 1977-10-11 Monsanto Company Preparation of n-phosphonomethyl glycine
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
EP0054862B1 (en) * 1980-12-18 1985-11-27 Schering Corporation Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
DK31784A (da) * 1983-01-28 1984-07-29 Schering Corp Phosphorholdige amidforbindelser, farmaceutiske kompositioner indeholdende disse, og fremgangsmaader til forbindelsernes fremstilling
US4939261A (en) * 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
EP0225292A3 (en) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
US4963539A (en) * 1987-09-10 1990-10-16 E. R. Squibb & Sons, Inc. Phosphonate and phosphonamide endopeptidase inhibitors
GB8726714D0 (en) * 1987-11-14 1987-12-16 Beecham Group Plc Compounds
EP0401963A1 (en) * 1989-04-13 1990-12-12 Beecham Group p.l.c. Phosphonopeptides with collagenase inhibiting activity
FR2652087B1 (fr) * 1989-09-15 1993-10-15 Bioprojet Ste Civile Derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques.

Also Published As

Publication number Publication date
EP0511940A3 (en) 1993-11-03
EP0511940A2 (en) 1992-11-04
MX9201953A (es) 1992-11-01
TW208704B (fi) 1993-07-01
HU9201430D0 (en) 1992-07-28
ZA923164B (en) 1992-11-25
NZ242546A (en) 1994-08-26
KR920021578A (ko) 1992-12-18
FI921884A (fi) 1992-11-02
IE921401A1 (en) 1992-11-04
US5155100A (en) 1992-10-13
AU1509192A (en) 1992-11-05
HUT61032A (en) 1992-11-30
AU655252B2 (en) 1994-12-08
FI921884A0 (fi) 1992-04-27
NO921719L (no) 1992-11-02
IL101633A0 (en) 1992-12-30
NO921719D0 (no) 1992-04-30
CA2067592A1 (en) 1992-11-02
JPH05170792A (ja) 1993-07-09

Similar Documents

Publication Publication Date Title
US5155100A (en) Phosphono/biaryl substituted dipeptide derivatives
US5294632A (en) Phosphono/biaryl substituted dipetide derivatives
US5354892A (en) Biaryl substituted 4-amino-butyric acid amides
US5250522A (en) Phosphono/biaryl substituted amino acid derivatives
US4316896A (en) Aminoacid derivatives as antihypertensives
US5273990A (en) Phosphono substituted tetrazole derivatives
EP0320118B1 (en) Peptides with collagenase inhibiting activity
US5550119A (en) Phosphono substituted tetrazole derivatives as ECE inhibitors
US4963539A (en) Phosphonate and phosphonamide endopeptidase inhibitors
JPH11509231A (ja) リン−含有システイン及びセリンプロテアーゼ阻害剤
KR20110053336A (ko) 통증 치료에 사용될 수 있는 아미노포스피닉 유도체
ES2237917T3 (es) Ciertos inhibidores tiolicos substituidos con heteroarilo de enzima conversora de endotelina.
EP0401963A1 (en) Phosphonopeptides with collagenase inhibiting activity
US5380921A (en) Aminophosponic acid derivative
EP0660840B1 (en) Phosphono substituted tetrazole derivatives
US5426103A (en) Certain macrocyclic lactam derivatives
WO1991015506A1 (en) Phosphonopeptides with collagenase inhibiting activity
WO1996019486A1 (en) Certain tetrazole derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
RH Patent void